Equities

Veracyte Inc

Veracyte Inc

Actions
  • Price (EUR)36.20
  • Today's Change0.00 / 0.00%
  • Shares traded137.00
  • 1 Year change+44.42%
  • Beta--
Data delayed at least 15 minutes, as of May 07 2021 07:01 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

  • Revenue in USD (TTM)117.48m
  • Net income in USD-34.91m
  • Incorporated2006
  • Employees320.00
  • Location
    Veracyte Inc6000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO 94080-7606United StatesUSA
  • Phone+1 (650) 243-6300
  • Fax+1 (650) 243-6301
  • Websitehttps://www.veracyte.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VCYT:NMQ since
announced
Transaction
value
Decipher Biosciences IncDeal completed03 Feb 202103 Feb 2021Deal completed-31.80%600.00m
Data delayed at least 15 minutes, as of May 07 2021 21:00 BST.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.